MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clgc.2026.102615

Медицинская библиотека · Clinical genitourinary cancer · 2026

Treatment and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer by Race, Initial Diagnosis, and Family History: Results From the TRUMPET Registry.

Karsh Lawrence, Hwang Clara, Symanowski James, Shevrin Daniel, Elsouda Dina, Russell David, Spalding James, Kral Pavol, El-Chaar Nader, Shore Neal

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

To better understand how treatment patterns, clinical outcomes, health-related quality of life, and healthcare resource utilization are impacted by initial prostate cancer diagnosis, prostate cancer family history, and race.

PATIENTS: We conducted three subgroup analyses using the TRUMPET US registry of metastatic castration-resistant prostate cancer (mCRPC) patients: 1) initial diagnosis of non-metastatic hormone-sensitive prostate cancer (HSPC) versus de novo metastatic HSPC; 2) with prostate cancer family history versus none; 3) Caucasians versus African Americans.

METHODS

Baseline characteristics, treatment patterns, health-related quality of life, and healthcare resource utilization were analyzed descriptively. Time-to-event outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazards models, adjusted based on clinically important variables, including disease biology factors and selected variables showing large standardized mean differences between groups.

RESULTS

This study included 832 patients with mCRPC. Patients with non-metastatic HSPC at initial diagnosis had a 32% lower risk of death than patients with de novo metastatic HSPC at initial diagnosis (adjusted HR: 0.68; 95% CI: 0.51, 0.91). Patients with prostate cancer family history had a significantly lower risk of death than patients with none (adjusted HR: 0.68; 95% CI: 0.51, 0.90). No statistically significant outcomes differences were identified between African American and Caucasian patients. Health-related quality of life changes were similar across all subgroups.

CONCLUSION

Our analyses suggest that initial diagnosis and prostate cancer family history may meaningfully impact patients' survival and clinical outcomes. Future dedicated, prospective research should further elucidate how each of these factors affectclinical outcomes in the mCRPC context.

Для цитирования: Karsh Lawrence, Hwang Clara, Symanowski James, Shevrin Daniel, Elsouda Dina, Russell David, Spalding James, Kral Pavol, El-Chaar Nader, Shore Neal. Treatment and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer by Race, Initial Diagnosis, and Family History: Results From the TRUMPET Registry.. Clinical genitourinary cancer. 2026. DOI: 10.1016/j.clgc.2026.102615.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.